Morgan Stanley Initiates Coverage of Shoulder Innovations with Overweight Rating

Morgan Stanley initiates coverage on Shoulder Innovations with an "Overweight" rating and a price target of $18.00. Analysts from Jefferies, Piper Sandler, and Goldman Sachs also provided recent ratings with varied perspectives on the company's potential performance. Shoulder Innovations is a commercial-stage medical technology company focused on transforming the shoulder surgical care market with advanced implant systems for shoulder arthroplasty.